Page last updated: 2024-10-27

fenofibrate and Angiosarcoma

fenofibrate has been researched along with Angiosarcoma in 1 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Research Excerpts

ExcerptRelevanceReference
"Fenofibrate is a hypolipidemic drug, which acts by activating the transcription factor PPARα."5.51Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. ( Alhousseiny, S; Ding, H; Jameel, M; Majeed, Y; Musthak, A; Shaheen, Y; Taha, T; Triggle, CR; Upadhyay, R, 2019)
"Fenofibrate is a hypolipidemic drug, which acts by activating the transcription factor PPARα."1.51Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. ( Alhousseiny, S; Ding, H; Jameel, M; Majeed, Y; Musthak, A; Shaheen, Y; Taha, T; Triggle, CR; Upadhyay, R, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Majeed, Y1
Upadhyay, R1
Alhousseiny, S1
Taha, T1
Musthak, A1
Shaheen, Y1
Jameel, M1
Triggle, CR1
Ding, H1

Other Studies

1 other study available for fenofibrate and Angiosarcoma

ArticleYear
Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro.
    Scientific reports, 2019, 04-19, Volume: 9, Issue:1

    Topics: Cell Division; Cell Line, Tumor; Fenofibrate; G2 Phase; Hemangiosarcoma; Humans; Hypolipidemic Agent

2019